Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NYSE - Delayed Quote USD

Bio-Rad Laboratories, Inc. (BIO)

Compare

234.75

-10.77

(-4.39%)

At close: April 3 at 4:00:02 PM EDT

230.00

-4.75

(-2.02%)

Pre-Market: 7:01:25 AM EDT

Further weakness as Bio-Rad Laboratories (NYSE:BIO) drops 5.0% this week, taking three-year losses to 61%

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...

Simply Wall St. 47 minutes ago

BIO
-4.39%
BIO-B
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.

Zacks 22 hours ago

BIO-B

BSX
Bio-Techne Opens New Customer Experience Centre in Germany

TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.

Zacks 3 days ago

TECH
-6.03%
QGEN
+0.87%
BIO-B
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate

Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.

Zacks 3 days ago

CRL
-5.56%
TMO

BIO-B
Alger Russell Innovation Index Updates for First Quarter 2025

Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, March 21, 2025, the Index will be rebalanced, and the following changes will be effective.

PR Newswire 17 days ago

HPE

PYPL

RBLX
Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%

Key Insights Significantly high institutional ownership implies Bio-Rad Laboratories' stock price is sensitive to their...

Simply Wall St. 27 days ago

BIO
-4.39%
BIO-B
Is Bio-Rad Laboratories, Inc. (BIO) the Best Medical Technology Stock to Buy According to Analysts?

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are going to take a look at where Bio-Rad Laboratories, Inc. (NYSE:BIO) stands against the other medical technology stocks. Growth and Drivers of the Global MedTech Market The MedTech sector is crucial in healthcare, which […]

Insider Monkey 30 days ago

BIO-B
Bio-Rad (BIO) International Revenue Performance Explored

Review Bio-Rad's (BIO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks last month

BIO-B
HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket

Henry Schein's fourth-quarter results reflect stable dental and medical end-markets.

Zacks last month

HSIC

CAH

BIO-B
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.

Zacks last month

VCYT

CAH

RMD
-4.33%
Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

GMED's fourth-quarter 2024 performance reflects strong synergies from the NuVasive merger.

Zacks last month

GMED

RMD
-4.33%
CAH
EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Exact Sciences' fourth-quarter 2024 performance benefits from the robust momentum in Cologuard adoption.

Zacks last month

EXAS

RMD
-4.33%
CAH
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.

Zacks last month

PEN

RMD
-4.33%
CAH
Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

MDT delivers strong earnings in the fiscal 2025 third quarter, with significant improvements in both gross and operating margins.

Zacks last month

MDT

RMD
-4.33%
CAH
BIO Stock Might Rise Following the Offer to Acquire Stilla

Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.

Zacks last month

BIO-B

RMD
-4.33%
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks last month

BIO-B
Bio-Rad price target lowered to $447 from $477 at RBC Capital

RBC Capital lowered the firm’s price target on Bio-Rad (BIO) to $447 from $477 and keeps an Outperform rating on the shares. The company reported a slight miss for Q4, with guidance coming in below consensus estimates on the top and bottom line, though based on peers’ results thus far, the low-single-digit top-line guide is not a major surprise, the analyst tells investors in a research note. RBC adds however that the lack of meaningful margin expansion by Bio-Rad was still surprising. Published

TipRanks last month

BIO
-4.39%
BIO-B
Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

Bio-Rad Laboratories ( NYSE:BIO ) Full Year 2024 Results Key Financial Results Revenue: US$2.57b (down 3.9% from FY...

Simply Wall St. last month

BIO
-4.39%
BIO-B
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.

Zacks last month

BIO-B

DGX

CAH
Bio-Rad set to acquire Stilla Technologies

Pending consultations and regulatory approval necessitates, the deal is expected to close by Q3 2025.

Medical Device Network last month

BIO-B

Performance Overview

Return	BIO	S&P 500 (^GSPC)
YTD	-28.54%	-8.25%
1-Year	-28.47%	+3.55%
3-Year	-58.88%	+18.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bio-Rad Laboratories, Inc. (BIO)

Further weakness as Bio-Rad Laboratories (NYSE:BIO) drops 5.0% this week, taking three-year losses to 61%

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

Bio-Techne Opens New Customer Experience Centre in Germany

Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate

Alger Russell Innovation Index Updates for First Quarter 2025

Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%

Is Bio-Rad Laboratories, Inc. (BIO) the Best Medical Technology Stock to Buy According to Analysts?

Bio-Rad (BIO) International Revenue Performance Explored

HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket

Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat

Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

BIO Stock Might Rise Following the Offer to Acquire Stilla

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Bio-Rad price target lowered to $447 from $477 at RBC Capital

Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Bio-Rad set to acquire Stilla Technologies

Performance Overview